ConductScience.org, home

Paper30909397

C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas.

Marona P and 5 others. Cells, 2019. Cited by 34 papers, by iCite.

Cite this record

ConductScience Library. C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas. Papers, record 30909397. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30909397

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas.
PubMed
Journal
Cells
PubMed
Year
2019
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
Citations, by iCite
34
iCite
Relative citation ratio, by iCite
1.37
iCite
Revised in PubMed
2020-03-09
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Marona PPaulinahttps://orcid.org/0000-0001-7664-250X
2Górka JJudytahttps://orcid.org/0000-0002-1298-329X
3Kotlinowski JJerzyhttps://orcid.org/0000-0002-3133-3364
4Majka MMarcinhttps://orcid.org/0000-0002-0429-681X
5Jura JJolanta
6Miekus KKatarzyna

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cell DifferentiationMajor topic
Drug Resistance, NeoplasmMajor topic
Kidney NeoplasmsMajor topic
Proto-Oncogene Proteins c-metMajor topic
Epithelial-Mesenchymal Transition
Humans
Phenotype

Source PubMed

Download CSV of topics

References92

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
120385023Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy.Mol Cancer2010https://conductscience.org/library/papers/20385023PubMed
223233163HGF regulates VEGF expression via the c-Met receptor downstream pathways, PI3K/Akt, MAPK and STAT3, in CT26 murine cells.Int J Oncol2013https://conductscience.org/library/papers/23233163PubMed
321102609MET signalling: principles and functions in development, organ regeneration and cancer.Nat Rev Mol Cell Biol2010https://conductscience.org/library/papers/21102609PubMed
47854453Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor.Nature1995https://conductscience.org/library/papers/7854453PubMed
528259294Understanding c-MET signalling in squamous cell carcinoma of the head & neck.Crit Rev Oncol Hematol2017https://conductscience.org/library/papers/28259294PubMed
61944272C-terminal truncated forms of Met, the hepatocyte growth factor receptor.Mol Cell Biol1991https://conductscience.org/library/papers/1944272PubMed
79258068C-met proto-oncogene expression in benign and malignant human renal tissues.J Urol1997https://conductscience.org/library/papers/9258068PubMed
828237182Correlation of c-Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib.Clin Genitourin Cancer2017https://conductscience.org/library/papers/28237182PubMed
913130303Targeting HIF-1 for cancer therapy.Nat Rev Cancer2003https://conductscience.org/library/papers/13130303PubMed
1021318618Development of second-generation VEGFR tyrosine kinase inhibitors: current status.Curr Oncol Rep2011https://conductscience.org/library/papers/21318618PubMed
1124827131A phase I study of cabozantinib (XL184) in patients with renal cell cancer.Ann Oncol2014https://conductscience.org/library/papers/24827131PubMed
129140397Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.Nat Genet1997https://conductscience.org/library/papers/9140397PubMed
1315070743Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair.Proc Natl Acad Sci U S A2004https://conductscience.org/library/papers/15070743PubMed
1426482279Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.Lancet Oncol2015https://conductscience.org/library/papers/26482279PubMed
1518485877The epithelial-mesenchymal transition generates cells with properties of stem cells.Cell2008https://conductscience.org/library/papers/18485877PubMed
1610353251The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.Nature1999https://conductscience.org/library/papers/10353251PubMed
1718676743Epithelial-mesenchymal transition in cervical cancer: correlation with tumor progression, epidermal growth factor receptor overexpression, and snail up-regulation.Clin Cancer Res2008https://conductscience.org/library/papers/18676743PubMed
1825381264Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models.Mol Cancer Ther2015https://conductscience.org/library/papers/25381264PubMed
1916585196Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma.Cancer Res2006https://conductscience.org/library/papers/16585196PubMed
208682590Overexpression of the met/HGF receptor in renal cell carcinomas.Int J Cancer1996https://conductscience.org/library/papers/8682590PubMed

See all 92 referencesDownload CSV of references

Cited by28

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 34 citations.

PMIDTitleJournalYearIn PapersSource
426451781D228 Attenuates Sorafenib Resistance in Renal Cell Carcinoma Models by Dual Targeting c-Met and AXL.Cells2026https://conductscience.org/library/papers/42645178PubMed
42524595Nuclear Mechanotransduction at the Crossroads: How Membrane Receptors Remodel the Perinuclear Cytoskeleton to Drive Cancer and Disease.Int J Biol Sci2026https://conductscience.org/library/papers/42524595PubMed
41463290Biomimetic Salivary Gland Cancer Spheroid Platform for In Vitro Recapitulation of Three-Dimensional Tumor-Stromal Interactions.Biomolecules2025https://conductscience.org/library/papers/41463290PubMed
40558302Molecular Genetics of Renal Cell Carcinoma: A Narrative Review Focused on Clinical Relevance.Curr Oncol2025https://conductscience.org/library/papers/40558302PubMed
39815326The endonuclease activity of MCPIP1 controls the neoplastic transformation of epithelial cells via the c-Met/CD44 axis.Cell Commun Signal2025https://conductscience.org/library/papers/39815326PubMed
39720556Recent advances in the treatment of non-small cell lung cancer with MET inhibitors.Front Chem2024https://conductscience.org/library/papers/39720556PubMed
39365364Retrospective study assessing the role of the androgen receptor in clear cell renal cell cancer patients treated with VEGFR inhibitors in monotherapy.Clin Transl Oncol2025https://conductscience.org/library/papers/39365364PubMed
39356364Design, synthesis and biological evaluation of thienopyridine derivatives as c-Met kinase inhibitors.Mol Divers2025https://conductscience.org/library/papers/39356364PubMed
39092291Renal cancer: signaling pathways and advances in targeted therapies.MedComm (2020)2024https://conductscience.org/library/papers/39092291PubMed
38693863Molecular and functional characterization of reversible-sunitinib-tolerance state in human renal cell carcinoma.J Cell Mol Med2024https://conductscience.org/library/papers/38693863PubMed
38687678Loss of tumor suppressor TMEM127 drives RET-mediated transformation through disrupted membrane dynamics.Elife2024https://conductscience.org/library/papers/38687678PubMed
38379085Downregulation of praja2 restrains endocytosis and boosts tyrosine kinase receptors in kidney cancer.Commun Biol2024https://conductscience.org/library/papers/38379085PubMed
38239394Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma.Cancer Drug Resist2023https://conductscience.org/library/papers/38239394PubMed
36982721An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines.Int J Mol Sci2023https://conductscience.org/library/papers/36982721PubMed
36839989Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario.Pharmaceutics2023https://conductscience.org/library/papers/36839989PubMed
36421797Tumorigenesis Mechanisms Found in Hereditary Renal Cell Carcinoma: A Review.Genes (Basel)2022https://conductscience.org/library/papers/36421797PubMed
35582583Dodging the bullet: therapeutic resistance mechanisms in pediatric cancers.Cancer Drug Resist2019https://conductscience.org/library/papers/35582583PubMed
35205843c-Met and EPHA7 Receptor Tyrosine Kinases Are Related to Prognosis in Clear Cell Renal Cell Carcinoma: Focusing on the Association with Myoferlin Expression.Cancers (Basel)2022https://conductscience.org/library/papers/35205843PubMed
35122106c-Met up-regulates the expression of PD-L1 through MAPK/NF-κBp65 pathway.J Mol Med (Berl)2022https://conductscience.org/library/papers/35122106PubMed
34681854LncRNAs in the Regulation of Genes and Signaling Pathways through miRNA-Mediated and Other Mechanisms in Clear Cell Renal Cell Carcinoma.Int J Mol Sci2021https://conductscience.org/library/papers/34681854PubMed

See all 28 cited byDownload CSV of cited by

Genes32

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
AXL558PubTator's text mininghttps://conductscience.org/library/genes/558NCBI Gene
BAIAP2L155971PubTator's text mininghttps://conductscience.org/library/genes/55971NCBI Gene
C8orf34116328PubTator's text mininghttps://conductscience.org/library/genes/116328NCBI Gene
CDH1999PubTator's text mininghttps://conductscience.org/library/genes/999NCBI Gene
CTNNB11499PubTator's text mininghttps://conductscience.org/library/genes/1499NCBI Gene
CXCL83576PubTator's text mininghttps://conductscience.org/library/genes/3576NCBI Gene
EPHB22048PubTator's text mininghttps://conductscience.org/library/genes/2048NCBI Gene
FLT32322PubTator's text mininghttps://conductscience.org/library/genes/2322NCBI Gene
FN12335PubTator's text mininghttps://conductscience.org/library/genes/2335NCBI Gene
GAS62621PubTator's text mininghttps://conductscience.org/library/genes/2621NCBI Gene
HGF3082PubTator's text mininghttps://conductscience.org/library/genes/3082NCBI Gene
HIF1A3091PubTator's text mininghttps://conductscience.org/library/genes/3091NCBI Gene
KDR3791PubTator's text mininghttps://conductscience.org/library/genes/3791NCBI Gene
KIT3815PubTator's text mininghttps://conductscience.org/library/genes/3815NCBI Gene
MET4233PubTator's text mininghttps://conductscience.org/library/genes/4233NCBI Gene
MST1R4486PubTator's text mininghttps://conductscience.org/library/genes/4486NCBI Gene
MTOR2475PubTator's text mininghttps://conductscience.org/library/genes/2475NCBI Gene
MYOD14654PubTator's text mininghttps://conductscience.org/library/genes/4654NCBI Gene
MYOG4656PubTator's text mininghttps://conductscience.org/library/genes/4656NCBI Gene

See all 32 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/30909397

GET https://conductscience.org/api/papers/v1/30909397/references?page=2